Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice

Nuclear Medicine and Biology

Volumn 31, Issue 2, 2004, Pages 213-223

  Lewis, Michael R ^a,b   Zhang, Jiuli ^a   Jia, Fang ^a   Owen, Nellie K ^b   Cutler, Cathy S ^a   Embree, Mary F ^a   Schultz, Jody ^c   Theodore, Louis J ^c   Ketring, Alan R ^a   Jurisson, Silvia S ^a   Axworthy, Donald B ^c  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c Poniard Pharmaceuticals Inc   (United States)

Author keywords

Biotin Streptavidin; Holmium 166; Lutetium 177; Pretargeting; Promethium 149; TAG 72

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BIOTIN LU 177; ACETIC ACID DERIVATIVE; HOLMIUM 166; HYBRID PROTEIN; LANTHANIDE; LUTETIUM 177; PROMETHIUM 149; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY STREPTAVIDIN; UNCLASSIFIED DRUG; B72.3 ANTIBODY; BIOTIN; CANCER ANTIBODY; DIAGNOSTIC AGENT; DOTA BIOTIN; DOTA-BIOTIN; DRUG DERIVATIVE; HOLMIUM; IMMUNOGLOBULIN FRAGMENT; LUTETIUM; ORGANOMETALLIC COMPOUND; PROMETHIUM; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; STREPTAVIDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; COLORECTAL TUMOR; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TARGETING; DRUG UPTAKE; MOUSE; NONHUMAN; NUDE MOUSE; RADIOIMMUNOTHERAPY; URINARY EXCRETION; XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; COLON TUMOR; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; EVALUATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEOPLASM; BIOTIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; HOLMIUM; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INJECTIONS, INTRAVENOUS; LUTETIUM; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; PROMETHIUM; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECOMBINANT FUSION PROTEINS; STREPTAVIDIN; TISSUE DISTRIBUTION;

EID: 12144289324     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2003.08.004     Document Type: Article

References (69)

1. 177Lu-CC49 a phase I/II study. Gynecol Oncol. 65:1997;94-101.
2. 90Y radioimmunotherapy in a mouse xenograft model. J Immunother. 16:1994;158.
3. 90Y delivery to mouse tumor xenografts. Tumor Targeting. 2:1996;156-157.
4. Axworthy DB, Theodore LJ, Gustavson LM, Reno JM. Biotinidase-resistant biotin-DOTA conjugates. US Patent 5,608,060, 1997
5. Axworthy D.B., Reno J.M., Hylarides M.D., Mallett R.W., Theodore L.J., Gustavson L.M., Su F.-M., Hobson L.J., Beaumier P.L., Fritzberg A.R. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA. 97:2000;1802-1807.
6. Barbet J., Peltier P., Bardet S., Vuillez J.P., Bachelot I., Denet S., Olivier P., Leccia F., Corcuff B., Huglo D., Proye C., Rouvier E., Meyer P., Chatal J.F. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA × anti-DTPA-indium bispecific antibody. J Nucl Med. 39:1998;1172-1178.
7. Battista P., Muraro R., Mammarella S., Curia M.C., Colasante A., Rosini S., Lesti G., Sacco R., French D., Frati L., Costantini R.M. Complementary reactivities of anti-carcinoembryonic antigen and antitumorassociated glycoprotein 72 monoclonal antibodies in lung carcinomas. Cancer Res. 50:1990;6987-6994.
8. Bos E.S., Kuijpers W.H.A., Meesters-Winters M., Pham D.T., de Haan A.S., van Doornmalen A.M., Kaspersen F.M., van Boeckel C.A.A., Gougeon-Bertrand F. In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer. Cancer Res. 54:1994;3479-3486.
9. Briesmeister JF, Ed., MCNP - a general Monte Carlo N-particle transport code, version 4C, Report LA-13709-M, Los Alamos National Laboratory, Los Alamos, NM; 2000
10. 111In-DOTA-biotin in an intraperitoneal tumor model. Cancer Biother Radiopharm. 15:2000;395.
11. Cremonesi M., Ferrari M., Chinol M., Stabin M.G., Grana C., Prisco G., Robertson C., Tosi G., Paganelli G. Three-step radioimmunotherapy with yttrium-90 biotin dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med. 26:1999;110-120.
12. Divgi C.R., Scott A.M., Dantis L., Capitelli P., Siler K., Hilton S., Finn R.D., Kemeny N., Kelsen D., Kostakoglu L., Schlom J., Larson S.M. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med. 36:1995;586-592.
13. Dosio F., Magnani P., Paganelli G., Samuel A., Chiesa G., Fazio F. Three-step tumor pre-targeting in lung cancer immunoscintigraphy. J Nucl Biol Med. 37:1993;228-232.
14. Eary J.F. Radioimmunotherapy of B-cell lymphoma. Ann Oncol. 2:(Suppl 2):1991;187-190.
15. Foulon C.F., Bigner D.D., Zalutsky M.R. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. Bioconjugate Chem. 10:1999;867-876.
16. Gautherot E., Le Doussal J.-M., Bouhou J., Manetti C., Martin M., Rouvier E., Barbet J. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J Nucl Med. 39:1998;1937-1943.
17. Goodwin D.A., Meares C.F., McCall M.J., McTigue M., Chaovapong W. Pretargeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med. 29:1988;226-234.
18. 90Y radioimmunotherapy. Cancer Res. 54:1994;5937-5946.
19. Guadagni F., Roselli M., Cosimelli M., Spila A., Cavaliere F., Tedesco M., Arcuri R., Abbolito M.R., Casale V., Pericoli M.N., Vecchione A., Casciani C.U., Greiner J.W., Schlom J. Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay. Cancer Res. 56:1996;5293-5298.
20. Johnston W.W., Szpak C.A., Thor A., Schlom J. Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3. Cancer Res. 46:1986;6462-6470.
21. Kairemo K.J. Radioimmunotherapy of solid cancers a review. Acta Oncol. 35:1996;343-355.
22. Kalofonos H.P., Rusckowski M., Siebecker D.A., Sivolapenko G.B., Snook D., Lavender J.P., Epenetos A.A., Hnatowich D.J. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies preliminary communication. J Nucl Med. 31:1990;1791-1796.
23. Ketring AR, Ehrhardt GJ, Embree MF, Bailey KD, Tyler TT, Gawenis JA, Jurisson SS, Engelbrecht HP, Smith CJ, Cutler CS. Production and supply of high specific activity radioisotopes for radiotherapy applications. Alasbimn J 5 (2003) http://www.alasbimnjournal.cl/revistas/19/ketring.html
24. V6/anti- gallium chelate antibodies. J Nucl Med. 39:1998;1769-1776.
25. Knox S.J., Goris M.L., Tempero M., Weiden P.L., Gentner L., Breitz H., Adams G.P., Axworthy D., Gaffigan S., Bryan K., Fisher D.R., Colcher D., Horak I.D., Weiner L.M. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res. 6:2000;406-414.
26. Kranenborg M.H.G.C., Boerman O.C., Griffiths G.L., Oosterwijk J.C., de Weijert M.C.A., McBride B., Hansen H.J., Oosterwijk E., Corstens F.H.M. Two-step targeting of RCC tumors in mice improved tumor uptake and retention with a bivalent chelate. J Nucl Med. 39:1998;78P.
27. Kuijpers W.H.A., Bos E.S., Kaspersen F.M., Veeneman G.H., van Boeckel C.A.A. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides a novel approach for two-step radioimmunotherapy of cancer. Bioconjugate Chem. 4:1993;94-102.
28. Le Doussal J.-M., Chetanneau A., Gruaz-Guyon A., Martin M., Gautherot E., Lehur P.A., Chatal J.F., Delaage M., Barbet J. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med. 34:1993;1662-1671.
29. Lewis M.R., Wang M., Jones L.A., Axworthy D.B., Welch M.J., Anderson C.J. Comparison of copper-64 radiopharmaceuticals for conventional and pretargeted radioimmunotherapy. J Labelled Cpd Radiopharm. 42:1999;S252-254.
30. 64Cu for tumor imaging and therapy. J Nucl Med. 44:2003;1284-1292.
31. Li W.P., Ma D.S., Higginbotham C., Hoffman T.J., Ketring A.R., Cutler C.S., Jurisson S.S. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol. 28:2001;145-154.
32. 99mTc-labeled morpholino, a DNA analog. J Nucl Med. 43:2002;384-391.
33. Lyubsky S., Madariaga J., Lozowski M., Mishriki Y., Schuss A., Chao S., Lundy J. A tumor-associated antigen in carcinoma of the pancreas defined by monoclonal antibody B72.3. Am J Clin Pathol. 89:1988;160-167.
34. Magnani P., Paganelli G., Modorati G., Zito F., Songini C., Sudati F., Koch P., Maecke H.R., Brancato R., Siccardi A.G., Fazio F. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med. 37:1996;967-971.
35. Magnani P., Paganelli G., Songini C., Samuel A., Sudati F., Siccardi A.G., Fazio F. Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma. Br J Cancer. 74:1996;825-831.
36. Mazur M.T., Shultz J.J. Prostatic adenocarcinoma. Evaluation of immunoreactivity to monoclonal antibody B72.3. Am J Clin Pathol. 93:1990;466-470.
37. Meredith R.F., Partridge E.E., Alvarez R.D., Khazaeli M.B., Plott G., Russell C.D., Wheeler R.H., Liu T., Grizzle W.E., Schlom J., LoBuglio A.F. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med. 37:1996;1491-1496.
38. Milenic D.E., Yokota T., Filpula D.R., Finkelman M.A.J., Dodd S.W., Wood J.F., Whitlow M., Snoy P., Schlom J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 51:1991;6363-6371.
39. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res. 1:1995;1447-1454.
40. 131I-CC49 in colorectal cancer. Cancer. 73:1994;1057-1066.
41. 111In-DTPA-biotin. Nucl Med Biol. 25:1998;95-99.
42. Ngai W.M., Reilly R.M., Polihronis J., Shpitz B. In vitro and in vivo evaluation of streptavidin immunoconjugates of the second generation TAG-72 monoclonal antibody CC49. Nucl Med Biol. 22:1995;77-86.
43. Nuti M., Yoshio A., Teramato Y.A., Mariani-Costantini R., Horan Hand P., Colcher D., Schlom J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer. 22:1982;539-545.
44. Nuti M., Mottolese M., Viora M., Donnorso P.R., Schlom J., Natali P.G. Use of monoclonal antibodies to human breast tumor associated antigens in fine needle aspirate cytology. Int J Cancer. 37:1986;493-498.
45. Ohuchi N., Thor A., Nose M., Fujita J., Kyogoku M., Schlom J. Tumor-associated glycoprotein (TAG-72) detected in adenocarcinomas and benign lesions of the stomach. Int J Cancer. 38:1986;643-650.
46. Paganelli G., Magnani P., Zito F., Villa E., Sudati F., Lopalco L., Rossetti C., Malcovati M., Chiolerio F., Seccamani E., Siccardi A.G., Fazio F. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 51:1991;5960-5966.
47. Paganelli G., Orecchia R., Jereczek-Fossa B., Grana C., Cremonesi M., De Braud F., Tradati N., Chinol M. Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. Eur J Nucl Med. 25:1998;1336-1339.
48. Pagel J.M., Hedin N., Subbiah K., Meyer D., Mallett R., Axworthy D., Theodore L.J., Wilbur D.S., Matthews D.C., Press O.W. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood. 101:2003;2340-2348.
49. Pavlinkova G., Booth B.J.M., Batra S.K., Colcher D. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Clin Cancer Res. 5:1999;2613-2619.
50. Press O.W., Corcoran M., Subbiah K., Hamlin D.K., Wilbur D.S., Johnson T., Theodore L., Yau E., Mallett R., Meyer D.L., Axworthy D. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 98:2001;2535-2543.
51. Saga T., Weinstein J.N., Jeong J.M., Heya T., Lee J.T., Le N., Paik C.H., Sung C., Neumann R.D. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res. 54:1994;2160-2165.
52. Sakahara H., Saga T. Avidin-biotin system for delivery of diagnostic agents. Adv Drug Deliv Rev. 37:1999;89-101.
53. 177lutetium-labeled immunoconjugate. Cancer Res. 51:1991;2889-2896.
54. Schlom J., Eggensperger D., Colcher D., Molinolo A., Houchens D., Miller L.S., Hinkle G., Siler K. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res. 52:1992;1067-1072.
55. Schultz J., Lin Y., Sanderson J., Zuo Y., Stone D., Mallett R., Wilbert S., Axworthy D. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 60:2000;6663-6669.
56. Sharkey R.M., Karacay H., Griffiths G.L., Behr T.M., Blumenthal R.D., Mattes M.J., Hansen H.J., Goldenberg D.M. Development of a streptavidin-anti- carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjugate Chem. 8:1997;595-604.
57. Stramignoni D., Bowen R., Atkinson B.F., Schlom J. Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer. 31:1983;543-552.
58. Tempero M., Leichner P., Dalrymple G., Harrison K., Augustine S., Schlom J., Anderson J., Wisecarver J., Colcher D. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers a phase I trial. J Clin Oncol. 15:1997;1518-1528.
59. Theodore LJ, Axworthy DB, Reno JM. Small molecular weight ligand hexose containing clearing agents. US patent 6,075,010, 2000.
60. Theodore LJ, Axworthy DB. Cluster clearing agents. US patent 6,172,010, 2001.
61. Thor A., Ohuchi N., Szpak C.A., Johnston W.W., Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 46:1986;3118-3124.
62. 111In-labeled DOTA-conjugated antibody fragments. Bioconjugate Chem. 12:2001;264-270.
63. Volkert W.A., Hoffman T.J. Therapeutic radiopharmaceuticals. Chem Rev. 99:1999;2269-2292.
64. Wang Y., Chang F., Zhang Y., Liu N., Liu G., Gupta S., Rusckowski M., Hnatowich D.J. Pretargeting with amplification using polymeric peptide nucleic acid. Bioconjugate Chem. 12:2001;807-816.
65. TM) for treatment of non-Hodgkin's lymphoma (NHL) initial phase I/II study results. Cancer Biother Radiopharm. 15:2000;15-29.
66. Wilbur D.S., Hamlin D.K., Pathare P.M., Ananda Weerawarna S. Biotin reagents for antibody pretargeting. Synthesis, radioiodination, and in vitro evaluation of water soluble biotinidase resistant biotin deriva-tives. Bioconjugate Chem. 8:1997;572-584.
67. Wilbur D.S., Chyan M.-K., Pathare P.M., Hamlin D.K., Frownfelter M.B., Kegley B.B. Biotin reagents for antibody pretargeting. 4. Selection of biotin conjugates for in vivo application based on their dissociation rate from avidin and streptavidin. Bioconjugate Chem. 11:2000;569-583.
68. Xu M., Real F.X., Welt S., Schussler M.H., Oettgen H.F., Old L.J. Expression of TAG-72 in normal colon, transitional mucosa, and colon cancer. Int J Cancer. 44:1989;985-989.
69. 90Y-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA)-biotin. Cancer Res. 62:2002;5755-5760.